{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:24:48Z","timestamp":1793982288636,"version":"4.8.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024NSFSC0629"],"award-info":[{"award-number":["2024NSFSC0629"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277102"],"award-info":[{"award-number":["22277102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004536","name":"Southwest Jiaotong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004536","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2682024ZTPY010"],"award-info":[{"award-number":["2682024ZTPY010"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.drudis.2024.104257","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T16:26:31Z","timestamp":1733588791000},"page":"104257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeting spleen tyrosine kinase (SYK): structure, mechanisms and drug discovery"],"prefix":"10.1016","volume":"30","author":[{"given":"Shuangqian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanxin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.104257_b0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1432-1033.1990.tb15433.x","article-title":"Purification and characterization of a cytosolic protein-tyrosine kinase from porcine spleen","volume":"188","author":"Kobayashi","year":"1990","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.drudis.2024.104257_b0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2024.104257_b0015","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3390\/cancers14040860","article-title":"Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas","volume":"14","author":"Profit\u00f3s-Pelej\u00e0","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2024.104257_b0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3390\/ijms23010081","article-title":"Targeting the ER\u03b2\/HER oncogenic network in KRAS mutant lung cancer modulates the tumor microenvironment and is synergistic with sequential immunotherapy","volume":"23","author":"Almotlak","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104257_b0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274390","article-title":"Targeting the splicing isoforms of spleen tyrosine kinase affects the viability of colorectal cancer cells","volume":"17","author":"Denis","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2024.104257_b0030","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1158\/0008-5472.CAN-18-2636","article-title":"Spleen tyrosine kinase-mediated autophagy is required for epithelial-mesenchymal plasticity and metastasis in breast cancer","volume":"79","author":"Shinde","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2024.104257_b0035","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40265-018-0927-1","article-title":"Fostamatinib: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2024.104257_b0040","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1124\/jpet.112.200832","article-title":"The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia","volume":"344","author":"Spurgeon","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2024.104257_b0045","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1021\/jm500228a","article-title":"Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase","volume":"57","author":"Currie","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104257_b0050","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/ijms24097728","article-title":"FDA-approved fluorinated heterocyclic drugs from 2016 to 2022","volume":"24","author":"Rizzo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104257_b0055","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade8272","article-title":"Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19","volume":"9","author":"Wigerblad","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2024.104257_b0060","doi-asserted-by":"crossref","first-page":"179.e1","DOI":"10.1016\/j.jtct.2022.12.015","article-title":"A phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease","volume":"29","author":"Lin","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.drudis.2024.104257_b0065","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jid.2023.10.005","article-title":"Alterations to the hidradenitis suppurativa serum proteome with spleen tyrosine kinase antagonism: proteomic results from a phase 2 clinical trial","volume":"144","author":"Flora","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.drudis.2024.104257_b0070","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.ekir.2023.09.024","article-title":"Randomized trial on the effect of an oral spleen tyrosine kinase inhibitor in the treatment of IgA nephropathy","volume":"8","author":"Tam","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.drudis.2024.104257_b0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.27144","article-title":"Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD)","volume":"99","author":"Kuter","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.drudis.2024.104257_b0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/oxfordjournals.jbchem.a002970","article-title":"Structure and function of Syk protein-tyrosine kinase","volume":"130","author":"Sada","year":"2001","journal-title":"J Biochem"},{"key":"10.1016\/j.drudis.2024.104257_b0085","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/0008-5472.CAN-13-2104","article-title":"Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma","volume":"74","author":"Hong","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2024.104257_b0090","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1128\/MCB.16.4.1305","article-title":"Phospholipase C-\u03b31 interacts with conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk","volume":"16","author":"Law","year":"1996","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.drudis.2024.104257_b0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0167-4889(96)00131-0","article-title":"Identification of the major sites of autophosphorylation of the murine protein-tyrosine kinase Syk","volume":"1355","author":"Furlong","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.drudis.2024.104257_b0100","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41392-021-00711-3","article-title":"TRIM31 facilitates K27-linked polyubiquitination of SYK to regulate antifungal immunity","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2024.104257_b0105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/(SICI)1097-0282(1998)47:3<243::AID-BIP4>3.0.CO;2-P","article-title":"Src homology-2 domains: structure, mechanisms, and drug discovery","volume":"47","author":"Sawyer","year":"1998","journal-title":"Biopolymers"},{"key":"10.1016\/j.drudis.2024.104257_b0110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jb\/mvp001","article-title":"Protein tyrosine kinase, Syk: a key player in phagocytic cells","volume":"145","author":"Tohyama","year":"2009","journal-title":"J Biochem"},{"key":"10.1016\/j.drudis.2024.104257_b0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbrc.2007.09.100","article-title":"Interdomain A is crucial for ITAM-dependent and -independent regulation of Syk","volume":"364","author":"Adachi","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2024.104257_b0120","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.bbapap.2007.10.008","article-title":"3D structure of Syk kinase determined by single-particle electron microscopy","volume":"1774","author":"Arias-Palomo","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.drudis.2024.104257_b0125","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1600-065X.2009.00837.x","article-title":"Autoinhibition and adapter function of Syk","volume":"232","author":"Kulathu","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.drudis.2024.104257_b0130","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.cellsig.2010.03.001","article-title":"The Src, Syk, and Tec family kinases: distinct types of molecular switches","volume":"22","author":"Bradshaw","year":"2010","journal-title":"Cell Signal"},{"key":"10.1016\/j.drudis.2024.104257_b0135","doi-asserted-by":"crossref","first-page":"7658","DOI":"10.1074\/jbc.RA119.008045","article-title":"A reevaluation of the spleen tyrosine kinase (SYK) activation mechanism","volume":"294","author":"Mansueto","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.104257_b0140","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1021\/jm201271b","article-title":"Discovery and development of spleen tyrosine kinase (SYK) inhibitors","volume":"55","author":"Singh","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104257_b0145","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1097-2765(02)00739-6","article-title":"Amplification of B cell antigen receptor signaling by a Syk\/ITAM positive feedback loop","volume":"10","author":"Rolli","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2024.104257_b0150","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/emboj.2008.62","article-title":"The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development","volume":"27","author":"Kulathu","year":"2008","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2024.104257_b0155","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2022.2131751","article-title":"Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib","volume":"34","author":"Cooper","year":"2023","journal-title":"Platelets"},{"key":"10.1016\/j.drudis.2024.104257_b0160","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.semnephrol.2018.05.019","article-title":"Role of the spleen tyrosine kinase pathway in driving inflammation in IgA nephropathy","volume":"38","author":"McAdoo","year":"2018","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.drudis.2024.104257_b0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/ni862","article-title":"The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion","volume":"4","author":"Flemming","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2024.104257_b0170","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41423-023-01049-2","article-title":"B1-cell-produced anti-phosphatidylserine antibodies contribute to lupus nephritis development via TLR-mediated Syk activation","volume":"20","author":"Ma","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2024.104257_b0175","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2024.104257_b0180","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/jlb.63.5.521","article-title":"Signal transduction by immunoglobulin Fc receptors","volume":"63","author":"S\u00e1nchez-Mejorada","year":"1998","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.drudis.2024.104257_b0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12455","article-title":"Tyrosine kinase signaling pathways in neutrophils","volume":"273","author":"Futosi","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.drudis.2024.104257_b0190","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fimmu.2016.00078","article-title":"Targeting Syk in autoimmune rheumatic diseases","volume":"7","author":"Deng","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2024.104257_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114360","article-title":"The prospects for targeting FcR as a novel therapeutic strategy in rheumatoid arthritis","volume":"183","author":"Wu","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2024.104257_b0200","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1111\/j.1742-4658.2011.08206.x","article-title":"The carbohydrate recognition domain of collectins","volume":"278","author":"Veldhuizen","year":"2011","journal-title":"FEBS J"},{"key":"10.1016\/j.drudis.2024.104257_b0205","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/cmi.2011.58","article-title":"C-type lectin receptor-induced NF-\u03baB activation in innate immune and inflammatory responses","volume":"9","author":"Kingeter","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2024.104257_b0210","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4049\/jimmunol.1601665","article-title":"Contact, collaboration, and conflict: signal integration of Syk-coupled C-type lectin receptors","volume":"198","author":"Ostrop","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2024.104257_b0215","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1357-2725(99)00022-9","article-title":"DAP12: a key accessory protein for relaying signals by natural killer cell receptors","volume":"31","author":"Campbell","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.drudis.2024.104257_b0220","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.immuni.2011.11.015","article-title":"Syk kinase-coupled C-type lectin receptors engage protein kinase C-\u03b4 to elicit Card9 adaptor-mediated innate immunity","volume":"36","author":"Strasser","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2024.104257_b0225","doi-asserted-by":"crossref","first-page":"ra71","DOI":"10.1126\/scisignal.2003973","article-title":"The tyrosine kinase Syk differentially regulates Toll-like receptor signaling downstream of the adaptor molecules TRAF6 and TRAF3","volume":"6","author":"Lin","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.drudis.2024.104257_b0230","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature01180","article-title":"The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors","volume":"420","author":"Horng","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104257_b0235","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.immuni.2008.06.004","article-title":"When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction","volume":"29","author":"O\u2019Neill","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2024.104257_b0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.767366","article-title":"Syk-MyD88 axis is a critical determinant of inflammatory-response in activated macrophages","volume":"12","author":"Yi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2024.104257_b0245","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1111\/jcmm.14893","article-title":"Chondroprotective and anti-inflammatory effects of amurensin H by regulating TLR4\/Syk\/NF-\u03baB signals","volume":"24","author":"Ma","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.drudis.2024.104257_b0250","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.bbagen.2015.12.012","article-title":"Syk negatively regulates TLR4-mediated IFN\u03b2 and IL-10 production and promotes inflammatory responses in dendritic cells","volume":"1860","author":"Yin","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.drudis.2024.104257_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117514","article-title":"Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK)","volume":"96","author":"Wang","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2024.104257_b0260","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2141.2006.06024.x","article-title":"The pathogenesis of immune thrombocytopaenic purpura","volume":"133","author":"Cooper","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2024.104257_b0265","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.186.7.1027","article-title":"A critical role for Syk in signal transduction and phagocytosis mediated by Fc\u03b3 receptors on macrophages","volume":"186","author":"Crowley","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2024.104257_b0270","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.drudis.2010.05.001","article-title":"Spleen tyrosine kinases: biology, therapeutic targets and drugs","volume":"15","author":"Riccaboni","year":"2010","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2024.104257_b0275","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2332\/allergolint.R-07-158","article-title":"Th17 cells and rheumatoid arthritis\u2014from the standpoint of osteoclast differentiation\u2014","volume":"57","author":"Sato","year":"2008","journal-title":"Allergol Int"},{"key":"10.1016\/j.drudis.2024.104257_b0280","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2177\/jsci.38.398","article-title":"The importance of B cell-T cell interaction in autoimmune diseases","volume":"38","author":"Iwata","year":"2015","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"10.1016\/j.drudis.2024.104257_b0285","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/art.39559","article-title":"Enhanced tyrosine phosphatase activity underlies dysregulated B cell receptor signaling and promotes survival of human lupus B cells","volume":"68","author":"Fleischer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.drudis.2024.104257_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102887","article-title":"Systemic lupus erythematosus-complicating immune thrombocytopenia: from pathogenesis to treatment","volume":"132","author":"Jiang","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.drudis.2024.104257_b0295","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41423-019-0254-9","article-title":"BANK1 interacts with TRAF6 and MyD88 in innate immune signaling in B cells","volume":"17","author":"Georg","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2024.104257_b0300","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cei\/uxac096","article-title":"A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models","volume":"211","author":"Cho","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.drudis.2024.104257_b0305","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/ibd\/izx031","article-title":"Genetic and pharmacological dissection of the role of spleen tyrosine kinase (Syk) in intestinal inflammation and immune dysfunction in inflammatory bowel diseases","volume":"24","author":"Biagioli","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.drudis.2024.104257_b0310","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/ecco-jcc\/jjaa088","article-title":"Mincle\/Syk signalling promotes intestinal mucosal inflammation through induction of macrophage pyroptosis in Crohn\u2019s disease","volume":"14","author":"Gong","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.drudis.2024.104257_b0315","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/nyas.14240","article-title":"Preliminary exploration of the potential of spliceosome-associated protein 130 for predicting disease severity in Crohn\u2019s disease","volume":"1462","author":"Gong","year":"2020","journal-title":"Ann n y Acad Sci"},{"key":"10.1016\/j.drudis.2024.104257_b0320","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104257_b0325","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/13543784.2018.1459562","article-title":"Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia","volume":"27","author":"Bartaula-Brevik","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2024.104257_b0330","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bcp.14962","article-title":"Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia","volume":"88","author":"Lam","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2024.104257_b0335","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/blood-2011-02-333773","article-title":"SYK inhibition and response prediction in diffuse large B-cell lymphoma","volume":"118","author":"Cheng","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104257_b0340","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104257_b0345","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.tips.2024.08.006","article-title":"New insights into SYK targeting in solid tumors","volume":"45","author":"Joshi","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2024.104257_b0350","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2024.104257_b0355","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.immuni.2018.08.024","article-title":"SYK-CARD9 signaling axis promotes gut fungi-mediated inflammasome activation to restrict colitis and colon cancer","volume":"49","author":"Malik","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2024.104257_b0360","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1158\/0008-5472.CAN-06-1274","article-title":"Epigenetic silencing of novel tumor suppressors in malignant melanoma","volume":"66","author":"Muthusamy","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2024.104257_b0365","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.7150\/jca.91360","article-title":"AQP3 promotes the invasion and metastasis in cervical cancer by regulating NOX4-derived H2O2 activation of Syk\/PI3K\/Akt signaling axis","volume":"15","author":"Wang","year":"2024","journal-title":"J Cancer"},{"key":"10.1016\/j.drudis.2024.104257_b0370","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/0008-5472.CAN-14-0629","article-title":"SYK is a candidate kinase target for the treatment of advanced prostate cancer","volume":"75","author":"Ghotra","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2024.104257_b0375","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/1055-9965.EPI-13-1057","article-title":"Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention","volume":"23","author":"Karimi","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.drudis.2024.104257_b0380","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.7150\/ijbs.61229","article-title":"The spleen tyrosine kinase inhibitor, entospletinib (GS-9973) restores chemosensitivity in lung cancer cells by modulating ABCG2-mediated multidrug resistance","volume":"17","author":"Narayanan","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2024.104257_b0385","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/0008-5472.CAN-22-3645","article-title":"Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma","volume":"83","author":"Rohila","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2024.104257_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101085","article-title":"Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy","volume":"74","author":"Zhou","year":"2024","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drudis.2024.104257_b0395","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.canlet.2022.01.026","article-title":"SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer","volume":"530","author":"Li","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2024.104257_b0400","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0162-3109(00)00224-1","article-title":"Immunologically mediated signaling in basophils and mast cells: finding therapeutic targets for allergic diseases in the human Fc\u03b5R1 signaling pathway","volume":"48","author":"Oliver","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.drudis.2024.104257_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107168","article-title":"Recent advance of spleen tyrosine kinase in diseases and drugs","volume":"90","author":"Shao","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2024.104257_b0410","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1016\/j.cell.2022.09.030","article-title":"SYK coordinates neuroprotective microglial responses in neurodegenerative disease","volume":"185","author":"Ennerfelt","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2024.104257_b0415","doi-asserted-by":"crossref","first-page":"e1200","DOI":"10.1002\/ctm2.1200","article-title":"The microglial immunoreceptor tyrosine-based motif-Syk signaling pathway is a promising target of immunotherapy for Alzheimer\u2019s disease","volume":"13","author":"Wang","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.drudis.2024.104257_b0420","doi-asserted-by":"crossref","first-page":"e1178","DOI":"10.1002\/ctm2.1178","article-title":"Microglia rely on SYK signalling to mount neuroprotective responses in models of Alzheimer\u2019s disease and multiple sclerosis","volume":"13","author":"Ennerfelt","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.drudis.2024.104257_b0425","doi-asserted-by":"crossref","first-page":"46197","DOI":"10.1074\/jbc.M204029200","article-title":"Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen","volume":"277","author":"Miura","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.104257_b0430","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3324\/haematol.2020.265173","article-title":"Low-dose Btk inhibitors: an \u2018aspirin\u2019 of tomorrow?","volume":"106","author":"Payrastre","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2024.104257_b0435","doi-asserted-by":"crossref","first-page":"C1346","DOI":"10.1152\/ajpcell.00559.2005","article-title":"Pathological shear stress directly regulates platelet \u03b1IIb\u03b23 signaling","volume":"291","author":"Feng","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.drudis.2024.104257_b0440","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3748\/wjg.v26.i10.1005","article-title":"Role of spleen tyrosine kinase in liver diseases","volume":"26","author":"Kurniawan","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.drudis.2024.104257_b0445","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/hep.28680","article-title":"Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease","volume":"64","author":"Bukong","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2024.104257_b0450","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1358\/dof.2011.36.4.1588554","article-title":"Fostamatinib disodium","volume":"36","author":"McAdoo","year":"2011","journal-title":"Drugs Future"},{"key":"10.1016\/j.drudis.2024.104257_b0455","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s40262-022-01135-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of fostamatinib and its active moiety R406","volume":"61","author":"Matsukane","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.drudis.2024.104257_b0460","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2008-07-166439","article-title":"Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk","volume":"113","author":"Podolanczuk","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104257_b0465","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00262-016-1946-y","article-title":"The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients","volume":"66","author":"Colado","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.drudis.2024.104257_b0470","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1021\/acsmedchemlett.9b00621","article-title":"Discovery of lanraplenib (GS-9876): a once-daily spleen tyrosine kinase inhibitor for autoimmune diseases","volume":"11","author":"Blomgren","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2024.104257_b0475","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1182\/blood.V126.23.4928.4928","article-title":"The combination of the novel Syk inhibitor TAK659 with decitabine exerts synergistic cytotoxic effects against FLT3\/ITD mutated acute myeloid leukemia cells","volume":"126","author":"Stage","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104257_b0480","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/jpet.114.218164","article-title":"The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer","volume":"351","author":"Coffey","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2024.104257_b0485","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1124\/jpet.111.188441","article-title":"Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis","volume":"340","author":"Coffey","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2024.104257_b0490","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1182\/blood.V128.22.3970.3970","article-title":"HMPL-523, a novel SYK inhibitor showed anti-tumor activities in vitro and in vivo","volume":"128","author":"Yang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104257_b0495","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaci.2019.07.013","article-title":"Oral Janus kinase\/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis","volume":"144","author":"Pavel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2024.104257_b0500","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jaad.2023.04.027","article-title":"Oral SYK\/JAK inhibitor gusacitinib for the treatment of chronic hand eczema: results of a randomized phase 2 study","volume":"89","author":"Jimenez","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.drudis.2024.104257_b0505","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1016\/j.bmcl.2018.09.022","article-title":"Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease","volume":"28","author":"Barker","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2024.104257_b0510","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1124\/jpet.103.052316","article-title":"The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents","volume":"306","author":"Yamamoto","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2024.104257_b0515","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2010-03-274969","article-title":"PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model","volume":"117","author":"Reilly","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104257_b0520","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood.V120.21.3532.3532","article-title":"Efficacy of PRT060318, a novel highly specific SYK inhibitor, in acute lymphoblastic leukemia (ALL)","volume":"120","author":"Kohrer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104257_b0525","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/leu.2012.24","article-title":"Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration","volume":"26","author":"Hoellenriegel","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2024.104257_b0530","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1016\/j.bmc.2005.05.033","article-title":"Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives","volume":"13","author":"Hisamichi","year":"2005","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2024.104257_b0535","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1016\/j.bmcl.2011.07.082","article-title":"Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor","volume":"21","author":"Liddle","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2024.104257_b0540","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/gutjnl-2012-302615","article-title":"Inhibition of spleen tyrosine kinase as treatment of postoperative ileus","volume":"62","author":"van Bree","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2024.104257_b0545","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ardp.201500096","article-title":"Discovery of benzylidene derivatives as potent Syk inhibitors: synthesis, SAR analysis, and biological evaluation","volume":"348","author":"Zhang","year":"2015","journal-title":"Arch Pharm"},{"key":"10.1016\/j.drudis.2024.104257_b0550","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ejmech.2015.02.019","article-title":"LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors","volume":"93","author":"Li","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104257_b0555","doi-asserted-by":"crossref","first-page":"111495","DOI":"10.18632\/oncotarget.22847","article-title":"A novel orally available Syk\/Src\/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2024.104257_b0560","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/jpet.116.233155","article-title":"BI 1002494, a novel potent and selective oral spleen tyrosine kinase inhibitor, displays differential potency in human basophils and B cells","volume":"357","author":"Lamb","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2024.104257_b0565","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/all.13101","article-title":"Spleen tyrosine kinase inhibition blocks airway constriction and protects from Th2-induced airway inflammation and remodeling","volume":"72","author":"Tabeling","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.drudis.2024.104257_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106774","article-title":"Rule of five violations among the FDA-approved small molecule protein kinase inhibitors","volume":"191","author":"Roskoski","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2024.104257_b0575","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.3390\/molecules23123114","article-title":"Discovery of a natural Syk inhibitor from Chinese medicine through a docking-based virtual screening and biological assay study","volume":"23","author":"Wang","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2024.104257_b0580","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201800083","article-title":"Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors","volume":"351","author":"Huang","year":"2018","journal-title":"Arch Pharm"},{"key":"10.1016\/j.drudis.2024.104257_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115597","article-title":"Discovery of 3-(1H-benzo[d]imidazole-2-yl)-1H-pyrazol-4 -amine derivatives as novel and potent syk inhibitors for the treatment of hematological malignancies","volume":"258","author":"Cui","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104257_b0590","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1016\/j.bmcl.2008.09.106","article-title":"Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK)","volume":"18","author":"Farmer","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2024.104257_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116375","article-title":"Discovery and optimization of 4-pyrazolyl-2-aminopyrimidine derivatives as potent spleen tyrosine kinase (SYK) inhibitors","volume":"270","author":"Cervi","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104257_b0600","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/j.clml.2018.05.022","article-title":"An open-label, phase II trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in diffuse large B-cell lymphoma","volume":"18","author":"Burke","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.drudis.2024.104257_b0605","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jid.2020.11.031","article-title":"A phase 1b, randomized, single-center trial of topical cerdulatinib (DMVT-502) in patients with mild-to-moderate atopic dermatitis","volume":"141","author":"Piscitelli","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.drudis.2024.104257_b0610","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/1078-0432.CCR-18-1047","article-title":"Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed\/refractory B-cell malignancies","volume":"25","author":"Coffey","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2024.104257_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113393","article-title":"Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor","volume":"219","author":"Rao","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104257_b0620","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1039\/C9CS00720B","article-title":"Advances in covalent kinase inhibitors","volume":"49","author":"Abdeldayem","year":"2020","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2024.104257_b0625","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1042\/BJ20140793","article-title":"Modification by covalent reaction or oxidation of cysteine residues in the tandem-SH2 domains of ZAP-70 and Syk can block phosphopeptide binding","volume":"465","author":"Visperas","year":"2015","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2024.104257_b0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293548","article-title":"Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM","volume":"19","author":"Bashore","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2024.104257_b0635","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104257_b0640","first-page":"E40","article-title":"Efficacy, safety and pharmacology of oral ASN002, a novel Jak\/Syk inhibitor, in moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study","volume":"179","author":"Guttman-Yassky","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.drudis.2024.104257_b0645","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ccr.2014.01.022","article-title":"SYK is a critical regulator of FLT3 in acute myeloid leukemia","volume":"25","author":"Puissant","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2024.104257_b0650","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/18050","article-title":"Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase","volume":"398","author":"Meng","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104257_b0655","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1093\/emboj\/20.24.7085","article-title":"The non\u2010receptor tyrosine kinase Syk is a target of Cbl\u2010mediated ubiquitylation upon B\u2010cell receptor stimulation","volume":"20","author":"Rao","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2024.104257_b0660","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-018-03530-3","article-title":"Peli1 negatively regulates noncanonical NF-\u03baB signaling to restrain systemic lupus erythematosus","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624003829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624003829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T13:06:19Z","timestamp":1738587979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624003829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":132,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1359644624003829"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104257","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting spleen tyrosine kinase (SYK): structure, mechanisms and drug discovery","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104257"}}